1 / 10

Immunization Update 2007 Satellite Broadcast/Webcast August 9, 2007 Zoster Vaccine Segment

Immunization Update 2007 Satellite Broadcast/Webcast August 9, 2007 Zoster Vaccine Segment. Graphics subject to change. This material in the public domain. Herpes Zoster (Shingles). Caused by reactivation of varicella zoster virus Can occur years or decades after illness with chickenpox

talasi
Download Presentation

Immunization Update 2007 Satellite Broadcast/Webcast August 9, 2007 Zoster Vaccine Segment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunization Update 2007 Satellite Broadcast/Webcast August 9, 2007 Zoster Vaccine Segment Graphics subject to change. This material in the public domain.

  2. Herpes Zoster (Shingles) • Caused by reactivation of varicella zoster virus • Can occur years or decades after illness with chickenpox • Generally associated with normal aging and with anything that causes reduced immunocompetence • Lifetime risk of up to 30% in the United States • Estimated 500,000 to 1 million cases of zoster diagnosed annually in the U.S

  3. Complications of Herpes Zoster • Postherpetic neuralgia (can persist for weeks or months after rash resolves) • Ophthalmic zoster (involvement of the ophthalmic division of the trigeminal nerve and the eye) • Dissemination with generalized skin eruptions and involvement of the central nervous system, lung, liver, and pancreas

  4. Herpes Zoster Vaccine (Zostavax) • Contains live attenuated varicella virus in an amount that is approximately 14 times greater than that in regular varicella vaccine • Approved for persons 60 years and older • Administered by the subcutaneous route

  5. Herpes Zoster Vaccine Trial • Compared with the placebo group the vaccinated group had • 51% fewer episodes of zoster • Less severe disease • 66% less postherpetic neuralgia • No significant safety issues identified Source: NEJM 2005;352(22):2271-84.

  6. ACIP Recommendations* for Zoster Vaccine* • Single dose of zoster vaccine for adults 60 years of age and older whether or not they report a prior episode of shingles • Persons with a chronic medical condition may be vaccinated unless a contraindication or precaution exists for their condition *Provisional recommendations, October 2006

  7. Screening for Zoster Vaccine Eligibility • Screening for a history of varicella disease is NOT necessary or recommended to administer zoster vaccine to a person 60 years of age or older • Persons born in the U.S. before 1980 can be assumed to be immune regardless of their recollection of chickenpox

  8. Screening for Zoster Vaccine Eligibility • Do NOT test the person for varicella antibody • A negative test is more likely to indicate waning antibody level rather than true susceptibility • Seronegative persons should receive 2 doses of single antigen varicella vaccine

  9. Zoster Vaccine Storage and Handing • Must be stored at 5o F (-15o C) or colder AT ALL TIMES • Protect from light • Administer within 30 minutes of reconstitution

  10. CDC Vaccines and ImmunizationContact Information • Hotline (800) CDC-INFO • Email nipinfo@cdc.gov • Website www.cdc.gov/nip • Broadcast Updates and Resources Web Page www.cdc.gov/vaccines/ed/broadcasts.htm

More Related